A Study Comparing Two Types of Spinal Anesthesia (Bupivacaine vs Levobupivacaine) in Patients Undergoing Urological Surgeries

COMPARISON OF 0.5% BUPIVACAINE AND 0.5% LEVOBUPIVACAINE UNDER SPINAL ANESTHESIA IN UROLOGICAL SURGERIES - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094671

Enrollment

100

Registered

2025-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: 0.5% BUPIVACAINE: 0.5% BUPIVACAINE 2.5mL WILL BE ADMINISTERED VIA 26G QUINCKE SPINAL NEEDLE AT LUMBAR INTRATHECAL SPACE Intervention2: 0.5% LEVOBUPIVACAINE: 0.5% LEVOBUPIVACAINE 2.5mL W

Eligibility

Inclusion criteria

Inclusion criteria: -Patients aged between 18 and 75 years will be included. -Only those with ASA (American Society of Anesthesiologists) physical status classification I or II (indicating healthy individuals or those with mild systemic disease) will be considered. -Patients scheduled to undergo elective urological surgery under spinal anesthesia will be eligible. -Written informed consent will be obtained from all participants.

Exclusion criteria

Exclusion criteria: Patients with a known allergy to amide local anesthetics will be excluded. Individuals with severe cardiovascular, hepatic, renal, or neurological disorders will not be eligible. Patients with contraindications to spinal anesthesia?such as spinal deformities, neurological disorders, or increased intracranial pressure?will be excluded. Those with blood clotting disorders or currently on anticoagulant therapy will not be included. Patients who refuse to participate in the study will be excluded. Individuals with class II obesity (BMI MORE THAN EQUAL TO 30 kgm?) will be excluded. Pregnant or lactating women will not be eligible to participate.

Design outcomes

Primary

Measure	Time frame
1. Time of onset of Sensory blockade 2. Time of onset of Motor blockade 3. Duration of sensory and motor block 4. Cardiovascular side effects associated with both the drugs Timepoint: 1. Time of onset of Sensory blockade- 5 hours 2. Time of onset of Motor blockade- 5 hours 3. Duration of sensory and motor block- 5 hours 4. Cardiovascular side effects associated with both the drugs- 5 hours	—

Secondary

Measure	Time frame
1. Cardiovascular side effects 2. Other post-operative complicationsTimepoint: 5 hours	—

Countries

India

Contacts

Public ContactDr Abhijith A

Healthway Hospitals Pvt Ltd

drsandeeppawar7@gmail.com9881054608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026